Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis

By sjmartinez • April 27, 2023

Spiera R, Kuwana M, Khanna D, Hummers L, Frech TM, Stevens W, Matucci-Cerinic M, Kafaja S, Distler O, Jun JB, Levy Y, Leszcyzński P, Gordon J, Steen V, Lee EB, Jankowski T, Litinsky I, Chung L, Hsu V, Mayes M, Sandorfi N, Simms RW, Finzel S, de Vries-Bouwstra J, Constantine S, Dgetluck N, Dinh Q, Bloom BJ, Furst DE, White B, Denton CP; RESOLVE-1 Study Group. Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol. 2023 Apr 26. doi: 10.1002/art.42510. Epub ahead of print. PMID: 37098795.

Tags: Publications, Rheumatology

Training Stage, Program Pedigree, Degree Pathway, and Research Productivity among United States Gastroenterology Fellows

Stirrat TS, Tian T, Solanky P, Apte S, Shahrin S, Flatley M, Thiru S, Kakde S, Kanth P. Training Stage, Program Pedigree, Degree Pathway, and[...]

Response by Fonarow et al to Letter Regarding Article, “Improving Heart Failure Quality of are Over the First Twenty Years: The Get With The Guidelines-Heart Failure Program”

Tang AB, Greene SJ, Fonarow GC. Response by Fonarow et al to Letter Regarding Article, "Improving Heart Failure Quality of are Over the First Twenty[...]

Silicosis in the Artificial Stone Countertop Industry: An Official American Thoracic Society Workshop Report

Gandhi SA, Liu GY, Fazio JC, Amubieya O, Barnes H, Cavalin C, Cohen RA, Fireman E, Garcia SR, Harrison RJ, Houlroyd JL, Hua JT, Jones[...]